University of Worcester Worcester Research and Publications
 
  USER PANEL:
  ABOUT THE COLLECTION:
  CONTACT DETAILS:

Melatonin supplementation in the management of obesity and obesity-associated disorders: a review of physiological mechanisms and clinical applications

Genario, R., Cipolla-Neto, J., Bueno, Allain ORCID: https://orcid.org/0000-0002-9456-8558 and Santos, H.O. (2020) Melatonin supplementation in the management of obesity and obesity-associated disorders: a review of physiological mechanisms and clinical applications. Pharmacological Research. ISSN 1043-6618 (In Press)

[img] Text
Bueno-9863-2020-AAM-Melatonin-supplementation-in-the-management-of-obesity-and-obesity-associated-disorders-a-review-of-physiological-mechanisms-and-clinical-applications (1).pdf - Accepted Version
Restricted to Repository staff only until 17 October 2021.
Available under License Creative Commons Attribution Non-commercial No Derivatives.

Download (479kB) | Request a copy

Abstract

Despite the evolving advances in clinical approaches to obesity and its inherent comorbidities, the therapeutic challenge persists. Among several pharmacological tools already investigated, recent studies suggest that melatonin supplementation could be an efficient therapeutic approach in the context of obesity. In the present review, we have amalgamated the evidence so far available on physiological effects of melatonin supplementation in obesity therapies, addressing its effects upon neuroendocrine systems, cardiometabolic biomarkers and body composition. Most studies herein appraised employed melatonin supplementation at dosages ranging from 1 to 20 mg/day, and most studies followed up participants for periods from 3 weeks to 12 months. Overall, it was observed that melatonin plays an important role in glycaemic homeostasis, in addition to modulation of white adipose tissue activity and lipid metabolism, and mitochondrial activity. Additionally, melatonin increases brown adipose tissue volume and activity, and its antioxidant and anti-inflammatory properties have also been demonstrated. There appears to be a role for melatonin in adiposity reduction; however, several questions remain unanswered, for example melatonin baseline levels in obesity, and whether any seeming hypomelatonaemia or melatonin irresponsiveness could be clarifying factors. Supplementation dosage studies and more thorough clinical trials are needed to ascertain not only the relevance of such findings but also the efficacy of melatonin supplementation.

Item Type: Article
Additional Information:

The full-text cannot be supplied for this item. Please check availability with your local library or Interlibrary Requests Service.

Uncontrolled Discrete Keywords: obesity therapy, weight loss, melatonin, obesity, endocrinology
Subjects: Q Science > Q Science (General)
R Medicine > R Medicine (General)
R Medicine > RM Therapeutics. Pharmacology
Divisions: College of Health, Life and Environmental Sciences > School of Science and the Environment
Related URLs:
Depositing User: Allain Bueno
Date Deposited: 16 Oct 2020 10:03
Last Modified: 07 Dec 2020 17:14
URI: https://eprints.worc.ac.uk/id/eprint/9863

Actions (login required)

View Item View Item
 
     
Worcester Research and Publications is powered by EPrints 3 which is developed by the School of Electronics and Computer Science at the University of Southampton. More information and software credits.